Home » News » Government to supply AstraZeneca vaccine from the 24th (general)

Government to supply AstraZeneca vaccine from the 24th (general)

Input 2021.02.08 19:33 | Revision 2021.02.08 20:15

For 750,000 people… Elderly vaccination controversy and variant uselessness still remains

AstraZeneca’s new coronavirus infection (Corona 19) vaccine will be supplied in Korea from the 24th.

The quarantine authorities said on the 8th that “it is expected to be supplied sequentially for several days from the 24th.” The amount introduced is for 750,000 people (for 1.5 million times). SK Bioscience supplies it through domestic consignment production. A total of 10 million people will be brought into Korea by the third quarter.

AstraZeneca’s COVID-19 vaccine. /yunhap news

Excluding about 60,000 Pfizer vaccines (117,000 doses), which will be introduced after the middle of this month, it is the first vaccine to be used for large-scale vaccinations to medical staff and elderly people over 65 years old in the second quarter. Apart from the 10 million people, about 1.3 million people (2.6 million doses) will be added to Korea through the COVEX facility in the first half.

On the 10th, the Ministry of Food and Drug Safety will hold the final 3rd expert advisory meeting (final inspection committee) for this vaccine and decide whether to approve it. Although the approval is expected to be done without difficulty, opinions are still divided on whether or not to immunize the elderly, who lacked clinical data. On the 5th, the Central Pharmacist Review Committee, an advisory group from the Ministry of Food and Drug Safety, recommended that adults 18 years of age or older be permitted to use it, and that the vaccination committee of the Korea Centers for Disease Control and Prevention should determine whether or not to immunize the elderly.

“It doesn’t mean that it’s not effective for the elderly, but it means that the results to judge the effect are insufficient, so you have to make a careful decision.” “Perhaps this week, the approval content was decided through the final inspection committee of the Ministry of Food and Drug Safety. It is planned, and we will decide whether to adjust the vaccination plan through the Vaccination Specialized Committee (of the Korea Disease Administration).”

The vaccine remains effective against the British mutant virus, but it is reported to academia that it is significantly less effective against the South African mutant virus. According to the Wall Street Journal (WSJ) that day, a clinical trial conducted by a research team at Oxford University in England and South Africa in 2026 patients showed that the effectiveness of this vaccine was only about 10-20%, and it was not able to prevent the onset of symptoms during infection.

Prime Minister Jeong Sye-gyun said in a questionnaire to the National Assembly on the same day, “By the end of September, 70% of the people will be vaccinated, and by November, about two months later, collective immunity will be formed.” Said.

– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.